BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 112 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2021. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,529 | +110.8% | 7,850 | +271.0% | 0.00% | – |
| Q2 2023 | $10,686 | +71140.0% | 2,116 | -72.3% | 0.00% | – |
| Q1 2023 | $15 | +150.0% | 7,627 | +120.1% | 0.00% | – |
| Q4 2022 | $6 | -99.9% | 3,465 | -18.9% | 0.00% | – |
| Q3 2022 | $7,000 | -36.4% | 4,275 | -4.0% | 0.00% | – |
| Q2 2022 | $11,000 | +10.0% | 4,455 | +25.2% | 0.00% | – |
| Q1 2022 | $10,000 | -83.3% | 3,558 | -68.4% | 0.00% | -100.0% |
| Q4 2021 | $60,000 | +200.0% | 11,249 | +367.9% | 0.00% | 0.0% |
| Q3 2021 | $20,000 | -16.7% | 2,404 | +23.5% | 0.00% | 0.0% |
| Q2 2021 | $24,000 | -33.3% | 1,947 | +31.2% | 0.00% | 0.0% |
| Q1 2021 | $36,000 | -53.8% | 1,484 | -39.2% | 0.00% | -50.0% |
| Q4 2020 | $78,000 | -81.7% | 2,439 | -82.8% | 0.00% | -60.0% |
| Q3 2020 | $427,000 | +306.7% | 14,140 | +466.5% | 0.01% | +25.0% |
| Q2 2020 | $105,000 | – | 2,496 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |